文献速递脑血管病外科神经重症

动脉瘤性蛛网膜下腔出血患者接受磺脲类药物的结局:倾向调整分析

Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage Receiving Sulfonylureas: A Propensity-Adjusted Analysis.
PubMed 文献 · World Neurosurg · 2023-05-24

单中心回顾性分析2007年8月1日至2019年7月31日治疗的1013例动脉瘤性蛛网膜下腔出血患者,其中129例(13%)入院时合并糖尿病,16例(12%)正在使用磺脲类药物。糖尿病患者良好结局比例低于非糖尿病患者(40%[52/129] vs 51%[453/884],P=0.03);糖尿病患者的倾向调整多因素分析中,磺脲类使用与良好结局相关(OR 3.90,95%CI 1.05-15.9,P=0.046)。作者结论认为糖尿病与不良神经结局强相关,磺脲类可减轻不良结局,但需进一步研究人体给药剂量、时机和疗程。

要点

  • 糖尿病患者良好结局比例低于非糖尿病患者(40%[52/129] vs 51%[453/884],P=0.03)。
  • 糖尿病患者中磺脲类使用与良好结局相关(OR 3.90,95%CI 1.05-15.9,P=0.046)。
  • 作者结论认为结果支持磺脲类可能的神经保护作用,但需进一步研究人体剂量、时机和疗程。

核心结论

  • 糖尿病与动脉瘤性蛛网膜下腔出血后不良神经结局强相关。
  • 本队列中磺脲类减轻了不良结局,支持部分临床前证据提示此类药物在动脉瘤性蛛网膜下腔出血中可能的神经保护作用。
  • 作者认为这些结果值得进一步研究人体给药的剂量、时机和疗程。

研究设计与样本

  • 单中心回顾性分析,纳入2007年8月1日至2019年7月31日在该机构接受治疗的动脉瘤性蛛网膜下腔出血患者,共分析1013例。
  • 糖尿病患者按入院时是否接受磺脲类治疗分组。
  • 主要结局为末次随访时良好神经状态(改良Rankin量表评分≤2)。
  • 未调整P值<0.20的变量纳入倾向调整多因素logistic回归分析,以识别良好结局的预测因素。

主要发现

  • 1013例动脉瘤性蛛网膜下腔出血患者中,129例(13%)入院时合并糖尿病,其中16例(12%)正在使用磺脲类药物。
  • 糖尿病患者良好结局比例低于非糖尿病患者(40%[52/129] vs 51%[453/884],P=0.03)。
  • 糖尿病患者的多因素分析中,磺脲类使用与良好结局相关(OR 3.90,95%CI 1.05-15.9,P=0.046)。
  • 糖尿病患者的多因素分析中,Charlson合并症指数<4与良好结局相关(OR 3.66,95%CI 1.24-12.1,P=0.02)。
  • 糖尿病患者的多因素分析中,无迟发性脑梗死与良好结局相关(OR 4.09,95%CI 1.20-15.5,P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Aneurysmal subarachnoid hemorrhage (aSAH) is associated with increased blood-brain barrier permeability, disrupted tight junctions, and increased cerebral edema. Sulfonylureas are associated with reduced tight-junction disturbance and edema and improved functional outcome in aSAH animal models, but human data are scant. We analyzed neurological outcomes in aSAH patients prescribed sulfonylureas for diabetes mellitus. METHODS: Patients treated for aSAH at a single institution (August 1, 2007-July 31, 2019) were retrospectively reviewed. Patients with diabetes were grouped by presence or absence of sulfonylurea therapy at hospital admission. The primary outcome was favorable neurologic status at last follow-up (modified Rankin Scale score ≤2). Variables with an unadjusted P-value of <0.20 were included in a propensity-adjusted multivariable logistic regression analysis to identify predictors of favorable outcomes. RESULTS: Of 1013 aSAH patients analyzed, 129 (13%) had diabetes at admission, and 16 of these (12%) were receiving sulfonylureas. Fewer diabetic than nondiabetic patients had favorable outcomes (40% [52/129] vs. 51% [453/884], P = 0.03). Among diabetic patients, sulfonylurea use (OR 3.90, 95% CI 1.05-15.9, P = 0.046), Charlson Comorbidity Index <4 (OR 3.66, 95% CI 1.24-12.1, P = 0.02), and absence of delayed cerebral infarction (OR 4.09, 95% CI 1.20-15.5, P = 0.03) were associated with favorable outcomes in the multivariable analysis. CONCLUSIONS: Diabetes was strongly associated with unfavorable neurologic outcomes. An unfavorable outcome in this cohort was mitigated by sulfonylureas, supporting some preclinical evidence of a possible neuroprotective role for these medications in aSAH. These results warrant further study on dose, timing, and duration of administration in humans.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Catapano JS, Koester SW, Bond KM, et al. Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage Receiving Sulfonylureas: A Propensity-Adjusted Analysis. World Neurosurg. 2023. PMID: 37236313. doi:10.1016/j.wneu.2023.05.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。